(NASDAQ: VYGR) Voyager Therapeutics's forecast annual revenue growth rate of 24.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.52%.
Voyager Therapeutics's revenue in 2026 is $34,459,000.On average, 13 Wall Street analysts forecast VYGR's revenue for 2026 to be $1,274,813,726, with the lowest VYGR revenue forecast at $712,549,951, and the highest VYGR revenue forecast at $3,189,653,078. On average, 13 Wall Street analysts forecast VYGR's revenue for 2027 to be $2,927,776,799, with the lowest VYGR revenue forecast at $603,855,890, and the highest VYGR revenue forecast at $9,155,194,714.
In 2028, VYGR is forecast to generate $3,962,650,236 in revenue, with the lowest revenue forecast at $1,207,711,781 and the highest revenue forecast at $14,364,376,038.